CN106290910A - The test kit of a kind of omnidistance C reactive protein and detection method thereof - Google Patents
The test kit of a kind of omnidistance C reactive protein and detection method thereof Download PDFInfo
- Publication number
- CN106290910A CN106290910A CN201610667790.8A CN201610667790A CN106290910A CN 106290910 A CN106290910 A CN 106290910A CN 201610667790 A CN201610667790 A CN 201610667790A CN 106290910 A CN106290910 A CN 106290910A
- Authority
- CN
- China
- Prior art keywords
- reagent
- crp
- quality
- test tube
- test kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Abstract
The invention discloses the test kit of a kind of omnidistance C reactive protein, including main reagent bag, standard curve card and quality-control product Quality Control list；Main reagent includes the anti-reagent A of calibration object, CRP, CRP anti-reagent B, magnetic particle reagent and quality-control product；Chemiluminescence is combined by the present invention with immunity magnetic particle, provide a kind of close to homogeneous reaction system, and have employed one-step method reaction pattern, detection sensitivity, elaboration are greatly improved, detection range expands, response time is greatly shortened, from starting to be loaded onto testing result, the time is less than 35min, hence it is evident that be faster than similar test kit；And can measure multiple sample on Full-automatic chemiluminescence apparatus, it is achieved the rapid mensuration of high flux of C reactive protein, accuracy is high, and high specificity, degree of accuracy and detection efficiency are enhanced simultaneously.
Description
Technical field
The invention belongs to technical field of immune assay, relate to detecting the magnetic of C reactive protein (CRP) content in serum
Particulate chemistry luminescence immunoassay test kit and detection method thereof.
Background technology
C reactive protein (C-reactiveprotein, CRP) is synthesized by hepatocyte, produces at period of fetus, non-placenta materna
Transmission.Its mechanism of production is: when body is infected or tissue damaged hinders, macrophage and other leukocyte etc. are activated, and produces
The cytokines such as interleukin-6 (IL-6), interleukin-1 (IL-1), TNF-a and other mediations
Thing, these cytokines and mediators arrive liver, cell cultured supernatant and epithelial cell synthesis CRP.Structurally, CRP contains 5
Polypeptide chain subunit, is noncovalently combined into dish type polymer, and molecular weight is 11.5 ten thousand～140,000, and CRP is a kind of typical anxious
Property Phasic proteins.
Conventional CRP measures and includes qualitative, sxemiquantitative and quantitative analysis, can be used for evaluating and infects, tissue injury and struvite
Disease.Measuring for conventional CRP, reference value is typically considered content clinically and is higher than 10 mg/litre.At healthy population blood
In liquid, CRP level is less than 5 mg/litre, and under various conditions, acute inflammation 4～in 8 hours, CRP value reaches about 20 to 500
Mg/litre.Than erythrocyte sedimentation rate (ESR) and numeration of leukocyte is more sensitive, more may be used as acute inflammation evaluation index for conventional CRP
Lean on.
The common purposes of hs-CRP can be as the supplementary means of risk of cardiovascular diseases identification.Coordinate traditional
Acute coronary syndrome clinical diagnosis uses, the early warning instruction can recurred as coronary artery disease or acute coronary syndrome
Thing.
The mankind are in the acute stage of tissue injury, and some plasma proteins of liver synthesis dramatically increase, and these protein is generally called
For acute phase protein, c reactive protein (CRP) is to change the most significantly one in acute phase protein.
CRP its content in normal human serum is atomic；Sustain damage at tissue, inflammation, infection or CRP can during tumor destruction
To steeply rise within a few hours, CRP is widely used in early diagnosis and the Differential Diagnosis of clinical disease, and its rising is visible
In: 1, tissue injury, infection, tumor, myocardial infarction and a series of active chronic inflammation disease, such as rheumatic arthritis, whole body
Property vasculitis, polymyalgia rheumatism；2, postoperative infection and the index of complication: patients after surgery CRP raises, postoperative 7-10 days
CRP level should decline, and does not reduces such as CRP or again raises, and prompting may accompanying infection or thromboembolism；3, can be as bacillary
Infect and the Differential Diagnosis of viral infection: most of bacterial infections can cause patients serum CRP to raise, and viral infection
Then majority does not raises.Recent study is sent out CRP level and is also occurred cardiovascular disease closely related with following, numerous studies data sheet
Bright, atheroma is also a chronic inflammation processes, and CRP slightly raises and coronary artery events, apoplexy and peripheral angiopathy
Relevant, it is an independent risk factor；The probability that high quick CRP (Hs-CRP) level rising person occurs acute apoplexy is normal
2 times of Healthy People, the probability of generation myocardial infarction is 3 times of normal person.European hypertension prevention and control guide (ESH/ESC) in 2003
Formal recommendation, hyperpietic need to detect hs-CRP level.
Hs-CRP range of linearity low side is less than conventional CRP, and this relatively low scope can expand use indication, C
Reactive protein is nonspecific, it is necessary to combine clinical symptoms comprehensive assessment, it is impossible to as specific disease or the risk of disease
Make a definite diagnosis foundation.
In prior art, the detection time length of C reactive protein, operation complexity, poor repeatability, it is unsuitable for emergency treatment and clinic
The needs that patient diagnoses in time.
Summary of the invention
The technical problem to be solved in the present invention is to overcome in prior art, and the detection time length of C reactive protein, operation are again
Miscellaneous, poor repeatability, it is unsuitable for emergency treatment and the problem of needs that clinical patient diagnoses in time, it is provided that the employing magnetic that a kind of accuracy is high
Particulate chemistry luminescence method measures the test kit of Bone Gla protein (BGP) content in human serum.
In order to solve above-mentioned technical problem, the invention provides following technical scheme:
The test kit of a kind of omnidistance C reactive protein, including main reagent bag, standard curve card and quality-control product Quality Control list
Composition；
Main reagent bag includes following components:
Calibration object, described calibration object be the buffer containing BSA that with the addition of the most commensurability CRP antigen calibration object,
The anti-reagent A of CRP, the anti-reagent A of described CRP is the CRP antibody concatenator of Fluorescein isothiocyanate (FITC) labelling, contains
The buffer of BSA；
CRP anti-reagent B, described CRP anti-reagent B is the CRP antibody concatenator of alkali phosphatase (AP) labelling, containing BSA's
Buffer；
Magnetic particle reagent, described magnetic particle reagent is magnetic particle and sheep anti-FITC antibody junctional complex, buffer containing BSA；
Quality-control product, described quality-control product is the buffer containing BSA that with the addition of different amounts of CRP antigen respectively；
Prepare calibration object, the anti-reagent A of CRP, CRP anti-reagent B, magnetic particle reagent respectively, be separately applied in packing container,
Obtain the test kit of omnidistance C reactive protein；
Principal curve card is containing 6 Concentraton gradient calibration points and corresponding luminous value, generates principal curve for matching；
Quality-control product Quality Control list provides quality-control product Quality Control scope.
Further, this test kit also includes that Sample dilution, described Sample dilution are the solution of BSA.
Further, this test kit also includes that concentrated cleaning solutions, described concentrated cleaning solutions are containing Tris, NaCl and surface
The buffer of activating agent.
Further, this test kit also includes luminous substrate solution, and described luminous substrate solution is containing LumigenAPS-5
The buffer of luminescent solution.
Needing testing sample is carried out pre-treatment during test kit provided by the present invention detection, processing method includes following step
Rapid:
1, sample pre-treatments
To clinical serum, 3000rpm is centrifuged 5 minutes, takes upper liquid and can be analyzed measuring.Testing sample 2-8 DEG C is deposited
Put and must not exceed 48 hours, if 48 hours do not detect, Ying Yu less than-20 DEG C preservation, but it is not to be exceeded 30 days.
2, prepare before experiment
Need before experiment to place to room temperature all reagent；It is ready to when disposable flat based tubes and magnetic separator and incubation use
In the plastic foil covering magnetic separator；Regulation water bath temperature is 37 DEG C；Prepare chemical luminescence detector, and read over instrument
Operation instructions.
3, reagent prepares
Before experiment, reagent each in test kit is put and fully mix on blending instrument；Should be the most suspended after the mixing of magnetic particle reagent
Liquid, without obvious coagulation.
4, the chemical luminescence immune analysis reagent box detection sample of above-mentioned detection CRP is utilized.The detection method of the present invention is such as
Under:
The detection method of the test kit of this whole process C reactive protein, comprises the following steps:
(1) sample-adding and immunoreation: take three test tubes and be separately added into 15 μ L calibration objects, 15 μ L quality-control products and 15 μ L and treat test sample
This；
(2), every test tube adds the 30 anti-reagent A of μ L and 30ul anti-reagent B, use covered rearing with plastic film test tube, shake gently
Swing test tube 30s, after mixing, be placed in water-bath 15min at 37 DEG C；
(3), every test tube adds 30 μ L magnetic particle reagent, uses covered rearing with plastic film test tube, gently tube shaken 30s,
Put water-bath 5min at 37 DEG C；
(4) washing: test tube is stood on magnetic separator 2 minutes, and then camber line topples over supernatant, by test tube and Magneto separate
Device is together upside down in absorbent paper and pats dry；
(5), often pipe adds 300 μ L cleanout fluid, use covered rearing with plastic film test tube, gently tube shaken 30s, after mixing,
Flat based tubes is stood on magnetic separator 2 minutes, and then camber line topples over supernatant, test tube and magnetic separator is together upside down in
Pat dry in absorbent paper；It is repeated 3 times；
(6) each test tube adds 200 μ L luminous substrate, vibration mixing 3s, detects luminous intensity with Chemiluminescence Apparatus.
The invention have the advantages that
1, using magnetic bead is solid phase, makes immunoreation closer to liquid phase, and reaction is more fully with rapid, and makes exempting from of combination
Epidemic disease complex is more prone to separate, and reduces non-specific adsorption.
2, the anti-reagent used is Monoclonal Antibody Mixture, makes immunoreactive affinity higher, and the life of monoclonal antibody
Product differences between batches are relatively small, it is easier to ensure product batch between stable.
3, use chemical luminous substrate solution, make the sensitivity of detection be improved, and the range of linearity is wider.
4, the foundation of this method can be that the exploitation of other test kits provides a kind of convenience, high sensitivity, accuracy and surely
Immunologic detection method qualitatively.
It is in place of the main innovation of the present invention:
1, chemiluminescence is combined by test kit of the present invention with immunity magnetic particle, it is provided that a kind of close to homogeneous anti-
Answering system, compared with prior art, test kit of the present invention has higher detection sensitivity and specificity, and has reached preferably
Performance parameter.
2, the magnetic particle reagent in test kit, anti-reagent, calibration object, quality-control product, cleaning concentrate, luminous substrate solution and
Sample dilution is the optimization formula under this reaction system, imitates the phase to the use of test kit and detection performance has provided and tried hard to keep
Barrier.
The magnetic microparticle chemiluminescence immune assay test kit of the detection CRP of the present invention mainly uses direct sandwich assay quantitatively to examine
Survey the content of CRP in the samples such as human serum；Pre-treatment to sample requires low, and pretreatment process is simple, can quick, high flux inspection
Survey gross sample；Have employed high special monoclonal antibody and superparamagnetic, high dispersive, magnetic microparticles that specific surface area is big, mainly
Reagent provides with the form of working solution, and the method for inspection is convenient and easy, has that specificity is high, highly sensitive, degree of accuracy is high, accuracy
High.The magnetic microparticle chemiluminescence immune assay test kit of the present invention, simple in construction, easy to use, low price, carries
Convenient.
Main advantages of the present invention are as follows:
1, conventional CRP detection kit clinically, its lowest detectable limit is generally 3～5mg/L, and sensitivity is relatively low.This
Bright described test kit remolding sensitivity is higher, and the range of linearity is relatively wide, can carry out infectious disease, cardiovascular and cerebrovascular disease etc. simultaneously
Diagnosis.
2, chemiluminescence is combined by test kit of the present invention with immunity magnetic particle, it is provided that a kind of close to homogeneous anti-
Answering system, compared with prior art, the present invention has higher specificity, sensitivity, it is thus achieved that the time of testing result is short, behaviour
Make mode easy.
3, the present invention is compared with other common detection methods, has good stability, the testing result advantage such as accurately.
Accompanying drawing explanation
Accompanying drawing is for providing a further understanding of the present invention, and constitutes a part for description, with the reality of the present invention
Execute example together for explaining the present invention, be not intended that limitation of the present invention.In the accompanying drawings:
Fig. 1 is the structural representation of the present invention；
Detailed description of the invention
Below in conjunction with accompanying drawing, the preferred embodiments of the present invention are illustrated, it will be appreciated that preferred reality described herein
Execute example be merely to illustrate and explain the present invention, be not intended to limit the present invention.
Embodiment
One, magnetic bead buffer solution formulation operations code: as a example by preparing 1L:
1, according to amount of preparation, select suitable vessel, add the pure water of 0.7kg700ml；
2, Tris 6.02g, NaN3 0.99g are weighed in container, mixing, it is stirred at room temperature 2 hours；
3, detection pH value of solution, should be about 10；
4, modulation pH value is 8.0；
5, Tween-20 2.76ml is measured；Weigh polygynax 0.99g；Tetracycline 0.03g；BSA 4.97g is in container
In, stir 1 hour, adjust pH value to 8.0 ± 0.05；
6, it is settled to 1L, adjusts pH value to 8.0 ± 0.05；
7, filter with 0.22um filter, be stored in 4 DEG C.
Two, the preparation process of magnetic particle reagent
The ferroso-ferric oxide microsphere glutaraldehyde of a diameter of 0.1 micron is activated, after room temperature mixes 4 hours, uses
0.01mol/L PBS pH7.4 buffer solution for cleaning three times, and suspend with this solution, concentration is 50-100mg/ml；Then,
Every milliliter of suspension adds sheep anti-FITC antibody 100 μ g, mixes incubations 3-8 hour in 37 DEG C；Use isopyknic 0.01mol/L
PBS 5%BSA pH7.4 buffer is closed 40 minutes in 37 DEG C；Finally, with 0.5%BSA 0.02mol/L Tris-HCl
PH8.0 buffer solution for cleaning three times, and prepare certain density working solution by above-mentioned magnetic bead buffer solution.
Two, alkali phosphatase AP and the coupling of anti crp monoclonal antibody
Antibody is immunoglobulin, containing amino (-NH2), uses SMCC activator to activate, generates maleimide
Amine-immunoglobulin；Maleimide-immunoglobulin contains and can add with the maleimide base group of-SH radical reaction
Containing the alkali phosphatase of-SH, antibody can be linked together with alkali phosphatase.
Three, Fluorescein isothiocyanate FITC and the coupling of AFP monoclonal antibody
FITC molecule and the conjugate of CRP monoclonal antibody are to be marked with common alkalies labelling method antagonist.
When FITC reacts with antibody protein in alkaline solution, the r amino of lysine and the sulfur carbon amine bond of fluorescein on protein
Close, form FITC-protein conjugate, i.e. fluorescent antibody or fluorescence conjugate.General multipotency combines 15-20, an IgG
Molecule can be in conjunction with the FITC of 2-8 molecule, its reaction equation following FITC-N=C=S+-NH2-protein → FITC-NS-C-
NH2-protein
Four, the preparation of calibration object/quality-control product:
1, peak: maximum concentration point is X, impact point concentration is A, B, C, D, E, F, during preparation V bulk solution, needs to add
The volume of raw material is the most as shown in table 1；
The preparation of table 1 calibration object
2, omnidistance C reactive protein (CRP) mensuration test kit CRP calibration object raw material (concentration is 100ug/ml) is dilute with sample
Releasing liquid (concrete formula is shown in embodiment 6) and being configured to concentration point is 6 concentration point.
3, after being completely dissolved, posting label in 2-8 DEG C of preservation, effect duration is 12 months.
Five, cleaning concentrate formulation operations code: as a example by preparing 1L:
1, according to amount of preparation, select suitable container, add water outlet 700ml, weigh Tris 12.11g；NaCl
312.43g；Tween-20 27.74g；Bronidox 1g；Triton X-1001g；
2, place 18 hours, adjust pH to 8.6 ± 0.05；Add pure water to 1L, filtration.
15 times of dilutions are carried out when 3, using.
Six, luminous substrate solution formulation operations code: as a example by preparing 1L:
1, according to amount of preparation, select suitable container, weigh Tris 36.36g；Na2SO3 10mg；SDS 1.0g；Gloss
Essence 3.27mg；Tween-20 0.31ml adjusts pH to 9.35；Add pure water to 1L, filtration.
2, test luminous value
Seven, Sample dilution formulation operations code: as a example by preparing 1L:
1, addition 500ml pure water is in container, weighs trihydroxy aminomethane 6g；NaCl 8.8g；BSA 60g；
Proclin 300 1ml, adjusts pH to 7.5 ± 0.05.
2, pure water is settled to 1L, filters.
Testing result:
Detection curve is shown in Fig. 1.
Zero standard point is carried out 20 retests, takes meansigma methods that zero standard measures on schedule plus the standard deviation of 2 times, be
Its sensitivity.The sensitivity of this method is≤1ug/ml.
Clinical trial
One, Analysis of test results
1., due to the reason such as methodology or antibody specificity, use the reagent of different manufacturer to examine with a sample
Survey may obtain different testing results, therefore, should directly not be compared to each other with different reagent detection acquired results, Yi Mianzao
Become the medical explanation of mistake.
2. quality-control product can be as when the reference frame of time reliable experiment result degree, and its measured value should be in the Quality Control of this batch of product
Within the scope of single permission.When testing result is near the higher limit of reference range, it is contemplated that sample is carried out validation test.
3. the testing result of this reagent is intended for clinical reference, should be in conjunction with its symptom/sign, disease to the clinical diagnosis and treatment of patient
History, other information summaries such as lab testing and therapeutic response consider.
4.CRP is a kind of acute phase reactive protein, raises the most rapidly in inflammation, tissue injury.Owing to it has
Complement activation and the function of promotion phagocytosis, therefore can play an important role in terms of non-specific infection.CRP content liter in serum
Height is found in multiple pathologic condition:
Infect: post-operative infection, SLE or leukemia accompanying infection, neonate or baby's septicemia, bacterial meningitis,
The Symptomatic urinary tract infection of child, various antibacterials, virus, mycoplasma infection.
The diseases such as inflammation, allergy, autoimmune disease, rheumatic fever, myocardial infarction, lung infraction, malignant tumor, burn are equal
Serum CRP level can be caused to increase.
Two, test kit performance indications of the present invention
The most linear
The range of linearity (0.6～175.0) ng/mL, correlation coefficient r >=0.9900.
2. accuracy
Deviation≤± 10%.
3. lowest detectable limit
Lowest detectable limit≤0.5ng/mL.
4. repeatability
Coefficient of variation CV≤8%.
5. difference between batch coefficient of variation CV≤15%.
6. unit conversion
Mg/L=1000ng/mL.
Finally it is noted that the foregoing is only the preferred embodiments of the present invention, it is not limited to the present invention,
Although being described in detail the present invention with reference to previous embodiment, for a person skilled in the art, it still may be used
So that the technical scheme described in foregoing embodiments to be modified, or wherein portion of techniques feature is carried out equivalent.
All within the spirit and principles in the present invention, any modification, equivalent substitution and improvement etc. made, should be included in the present invention's
Within protection domain.
Claims (5)
1. the test kit of an omnidistance C reactive protein, it is characterised in that include main reagent bag, standard curve card and Quality Control
Quality control list；
Described main reagent bag includes following components:
Calibration object, described calibration object be the buffer containing BSA that with the addition of the most commensurability CRP antigen calibration object,
The anti-reagent A of CRP, the anti-reagent A of described CRP is the CRP antibody concatenator of Fluorescein isothiocyanate (FITC) labelling, containing BSA
Buffer；
CRP anti-reagent B, described CRP anti-reagent B is the CRP antibody concatenator of alkali phosphatase (AP) labelling, the buffering containing BSA
Liquid；
Magnetic particle reagent, described magnetic particle reagent is magnetic particle and sheep anti-FITC antibody junctional complex, buffer containing BSA；
Quality-control product, described quality-control product is the buffer containing BSA that with the addition of different amounts of CRP antigen respectively；
Described principal curve card is containing 6 Concentraton gradient calibration points and corresponding luminous value, generates principal curve for matching；
Described quality-control product Quality Control list provides quality-control product Quality Control scope.
2. the test kit of omnidistance C reactive protein as claimed in claim 1, it is characterised in that also include Sample Dilution
Liquid, described Sample dilution is the solution of BSA.
3. the test kit of omnidistance C reactive protein as claimed in claim 1, it is characterised in that also include concentrating cleaning
Liquid, described concentrated cleaning solutions is the buffer containing Tris, NaCl and surfactant.
4. the test kit of the omnidistance C reactive protein as described in any one of claim 1-3, it is characterised in that also include sending out
Light substrate solution, described luminous substrate solution is the buffer containing LumigenAPS-5 luminescent solution.
5. the detection method of the test kit of C reactive protein as claimed in claim 1 omnidistance, it is characterised in that include with
Lower step:
(1) sample-adding and immunoreation: take three test tubes and be separately added into 15 μ L calibration objects, 15 μ L quality-control products and 15 μ L samples to be tested；
(2), every test tube adds the 30 anti-reagent A of μ L and 30ul anti-reagent B, use covered rearing with plastic film test tube, examination of vibrating gently
Pipe 30s, after mixing, is placed in water-bath 15min at 37 DEG C；
(3), every test tube adds 30 μ L magnetic particle reagent, use covered rearing with plastic film test tube, gently tube shaken 30s, put 37
Water-bath 5min at DEG C；
(4) washing: test tube is stood on magnetic separator 2 minutes, and then camber line topples over supernatant, by test tube and magnetic separator one
Pat dry with being upside down in absorbent paper；
(5), often pipe adds 300 μ L cleanout fluid, use covered rearing with plastic film test tube, gently tube shaken 30s, after mixing, will be flat
End test tube stands 2 minutes on magnetic separator, and then camber line topples over supernatant, and test tube and magnetic separator are together upside down in water suction
Pat dry on paper；It is repeated 3 times；
(6) each test tube adds 200 μ L luminous substrate, vibration mixing 3s, detects luminous intensity with Chemiluminescence Apparatus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610667790.8A CN106290910A (en) | 2016-08-12 | 2016-08-12 | The test kit of a kind of omnidistance C reactive protein and detection method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610667790.8A CN106290910A (en) | 2016-08-12 | 2016-08-12 | The test kit of a kind of omnidistance C reactive protein and detection method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106290910A true CN106290910A (en) | 2017-01-04 |
Family
ID=57671089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610667790.8A Pending CN106290910A (en) | 2016-08-12 | 2016-08-12 | The test kit of a kind of omnidistance C reactive protein and detection method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106290910A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019075769A1 (en) * | 2017-10-16 | 2019-04-25 | 苏州长光华医生物医学工程有限公司 | Method for detecting hypersensitive c-reactive protein |
| CN111007263A (en) * | 2019-12-25 | 2020-04-14 | 迈克生物股份有限公司 | Detection kit and detection method |
| CN112051403A (en) * | 2020-08-27 | 2020-12-08 | 武汉生之源生物科技股份有限公司 | C-reactive protein chemiluminescence immunoassay kit and preparation method and application thereof |
| CN112710842A (en) * | 2020-12-15 | 2021-04-27 | 深圳天辰医疗科技有限公司 | HsCRP detection kit and detection method of hsCRP |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101514991A (en) * | 2008-02-19 | 2009-08-26 | 北京科美东雅生物技术有限公司 | Alpha-fetoprotein magnetic particle chemoluminescence immunoassay kit and method for preparing same |
| CN101937000A (en) * | 2010-08-05 | 2011-01-05 | 北京倍爱康生物技术有限公司 | Magnetic particle separation chemiluminescence immunoassay method of human cystatin C |
| CN102901820A (en) * | 2012-09-29 | 2013-01-30 | 江阴泽成生物技术有限公司 | Immunoassay kit and immunodetection method for magnetic particle chemiluminescence of human tumor marker carbohydrate antigen 50 (CA50) |
| CN103344634A (en) * | 2013-07-17 | 2013-10-09 | 江阴泽成生物技术有限公司 | Chemiluminescence immune assay kit and method for magnetic particle of human alpha fetoprotein (AFP) |
| CN104330577A (en) * | 2014-11-17 | 2015-02-04 | 南方医科大学南方医院 | C-reactive protein quantitative determination kit and preparation method thereof |
| CN104820102A (en) * | 2015-05-05 | 2015-08-05 | 南京格耀生物科技有限公司 | Kit of detecting the content of Lp-PLA2 and CRP on the basis of chemiluminescence, and method and application thereof |
| CN105203748A (en) * | 2015-09-28 | 2015-12-30 | 成都博奥新景医学科技有限公司 | Quantitative detection kit for full-measuring-range C reaction protein |
-
2016
- 2016-08-12 CN CN201610667790.8A patent/CN106290910A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101514991A (en) * | 2008-02-19 | 2009-08-26 | 北京科美东雅生物技术有限公司 | Alpha-fetoprotein magnetic particle chemoluminescence immunoassay kit and method for preparing same |
| CN101937000A (en) * | 2010-08-05 | 2011-01-05 | 北京倍爱康生物技术有限公司 | Magnetic particle separation chemiluminescence immunoassay method of human cystatin C |
| CN102901820A (en) * | 2012-09-29 | 2013-01-30 | 江阴泽成生物技术有限公司 | Immunoassay kit and immunodetection method for magnetic particle chemiluminescence of human tumor marker carbohydrate antigen 50 (CA50) |
| CN103344634A (en) * | 2013-07-17 | 2013-10-09 | 江阴泽成生物技术有限公司 | Chemiluminescence immune assay kit and method for magnetic particle of human alpha fetoprotein (AFP) |
| CN104330577A (en) * | 2014-11-17 | 2015-02-04 | 南方医科大学南方医院 | C-reactive protein quantitative determination kit and preparation method thereof |
| CN104820102A (en) * | 2015-05-05 | 2015-08-05 | 南京格耀生物科技有限公司 | Kit of detecting the content of Lp-PLA2 and CRP on the basis of chemiluminescence, and method and application thereof |
| CN105203748A (en) * | 2015-09-28 | 2015-12-30 | 成都博奥新景医学科技有限公司 | Quantitative detection kit for full-measuring-range C reaction protein |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019075769A1 (en) * | 2017-10-16 | 2019-04-25 | 苏州长光华医生物医学工程有限公司 | Method for detecting hypersensitive c-reactive protein |
| CN111007263A (en) * | 2019-12-25 | 2020-04-14 | 迈克生物股份有限公司 | Detection kit and detection method |
| CN111007263B (en) * | 2019-12-25 | 2023-10-20 | 迈克生物股份有限公司 | Detection kit and detection method |
| CN112051403A (en) * | 2020-08-27 | 2020-12-08 | 武汉生之源生物科技股份有限公司 | C-reactive protein chemiluminescence immunoassay kit and preparation method and application thereof |
| CN112710842A (en) * | 2020-12-15 | 2021-04-27 | 深圳天辰医疗科技有限公司 | HsCRP detection kit and detection method of hsCRP |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104634980B (en) | The super quick detection kit of cardiac muscle troponin I and super quick detection method | |
| CN104330577B (en) | A kind of preparation method of c reactive protein quantitative determination reagent kit | |
| CN111337673B (en) | Synthetic polypeptide composition for novel coronavirus immunodetection and application | |
| CN101246163B (en) | Pyemia early diagnosis liquid phase chip and method for producing the same | |
| CN106290910A (en) | The test kit of a kind of omnidistance C reactive protein and detection method thereof | |
| CN102901812A (en) | Magnetic particle chemiluminescence immunoassay kit and assay method for human thyroglobulin antibodies (TGAb) | |
| CN101750492A (en) | Self-immunity hepatitis detection protein chip and kit thereof | |
| CN108152512A (en) | Heparin-binding protein detection kit and preparation method thereof | |
| CN105352946B (en) | A kind of kit quantitatively detecting Anti SS-B antibody IgG using magnetic microparticle chemiluminescence and preparation method thereof and detection method | |
| CN105259354B (en) | Kit for detecting tuberculosis T cell release gamma-interferon and use method of kit | |
| CN108414766A (en) | Kit for quantitatively detecting diabetes autoantibody and its application | |
| CN108593641A (en) | A kind of kit and method quantitatively detecting test substance in whole blood sample | |
| CN107907691A (en) | A kind of myoglobin assay kit and its application method | |
| JP2007101559A (en) | Standard diluent for multiplex assay | |
| CN106370860A (en) | Kit and test paper strip for serum immunoglobulin E colloidal gold chromatography quantitative detection | |
| CN107677808A (en) | A kind of immue quantitative detection reagent box of thyroglobulin and preparation method thereof and detection method | |
| ES2277018T3 (en) | METHOD, TEST AND EQUIPMENT FOR THE QUANTIFICATION OF HIV PROTEASE INHIBITORS. | |
| CN104487846B (en) | People's FXIII as the normalization controls of immunoassay | |
| CN106596924A (en) | Magnetic particle chemiluminescent immunoassay kit and detection method thereof | |
| Parry et al. | Detection of rubella antibody using an optical immunosensor | |
| CN101551396A (en) | Chemiluminscence immunoassay kit of hepatitis E virus IgG antibody and preparation method thereof | |
| CN106546729B (en) | Novel process method for removing serum matrix effect in dry immunofluorescence quantitative detection | |
| CN109142743A (en) | A kind of multinomial detection kit for exempting from liver antibody certainly | |
| CN108008136A (en) | A kind of T visceral leukosis viruses (HTLV) antibody chemical luminescence detection kit and preparation method thereof | |
| CN108267576A (en) | Modified CCP antigens and application thereof and antiCCP antibody detection kit and its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination |